Valuable lessons learned from failed bronchiectasis trial  

Results from the RESPIRE trials fell short of expectations but even so offer hope for bronchiectasis, providing important lessons for future clinical trials and disease management, experts say. The RESPIRE trials – together the largest clinical trial program ever conducted in bronchiectasis – evaluated 32.5 mg ciprofloxacin dry powder inhalation twice-daily as a treatment for ...

Already a member? Login to keep reading

© 2018 the limbic